The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice

Neuropsychopharmacology

Volumn 31, Issue 4, 2006, Pages 730-738

  Ahern, Todd H ^a   Javors, Martin A ^b   Eagles, Douglas A ^c   Martillotti, Jared ^c   Mitchell, Heather A ^a   Liles, Larry Cameron ^a   Weinshenker, David ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antidepressant; Epilepsy; Norepinephrine; Norepinephrine transporter; Seizure

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; DESIPRAMINE; FLUROTHYL; IMIPRAMINE; NORADRENALIN TRANSPORTER; PENTETRAZOLE; REBOXETINE; SERTRALINE; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFECT; ELECTRIC SHOCK; FEMALE; KNOCKOUT MOUSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN FUNCTION; SEIZURE; SEIZURE SUSCEPTIBILITY;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE BETA-HYDROXYLASE; DRUG ADMINISTRATION SCHEDULE; ELECTROSHOCK; FLUROTHYL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOLINES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PENTYLENETETRAZOLE; REACTION TIME; SEIZURES;

EID: 33645017331     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300847     Document Type: Article

References (64)

1. Arai S, Morita K, Kitayama S, Kumagai K, Kumagai M, Kihira K et al (2003). Chronic inhibition of the norepinephrine transporter in the brain participates in seizure sensitization to cocaine and local anesthetics. Brain Res 964: 83-90.
2. Baldessarini RJ (1989). Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiatr 50: 117-126.
3. Barry JJ (2003). The recognition and management of mood disorders as a comorbidity of epilepsy. Epilepsia 44(Suppl 4): 30-40.
4. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG et al (1999). Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19: 10494-10501.
5. Bergstrom DA, Kellar KJ (1979). Adrenergic and serotonergic receptor binding in rat brain after chronic desmethylimipramine treatment. J Pharmacol Exp Ther 209: 256-261.
6. Brent DA, Crumrine PK, Varma RR, Allan M, Allman C (1987). Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 80: 909-917.
7. Boylan LS, Flint LA, Labovitz DL, Jackson SC, Starner K, Devinsky O (2004). Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 62: 258-261.
8. Browning RA (1994). Anatomy of generalized seizures. In: MalaFosse A, Genton P, Hirsch E, Marescaux C, Broglin D, Bernasconi R (eds). Idiopathic Generalized Epilepsies: Clinical, Experimental and Genetic Aspects. John Libbey and Company Ltd: London. pp 399-413.
9. Brunello N, Mendlewicz J, Kasper S, Leonard B, Montgomery S, Nelson J et al (2002). The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 12: 461-475.
10. Caccia S, Cappi M, Fracasso C, Garattini S (1990). Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berlin) 100: 509-514.
11. Charlier C, Pinto E, Ansseau M, Plomteux G (2000). Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 15: 453-459.
12. Clifford DB, Rutherford JL, Hicks FG, Zorumski CF (1985). Acute effects of antidepressants on hippocampal seizures. Ann Neurol 18: 692-697.
13. Dennis T, Beauchemin V, Lavoie N (1994). Antidepressant-induced modulation of GABAA receptors and beta-adrenoceptors but not GABAB receptors in the frontal cortex of olfactory bulbectomised rats. Eur J Pharmacol 262: 143-148.
14. Eells JB, Clough RW, Browning RA, Jobe PC (2004). Comparative fos immunoreactivity in the brain after forebrain, brainstem, or combined seizures induced by electroshock, pentylenetetrazol, focally induced and audiogenic seizures in rats. Neuroscience 123: 279-292.
15. El-Mallakh RS, Paskitti ME (2001). The ketogenic diet may have mood-stabilizing properties. Med Hypotheses 57: 724-726.
16. Escorihuela RM, Boix F, Corda MG, Tobena A, Fernandez Teruel A (1989). Chronic but not acute antidepressant treatment increases pentetrazol-induced convulsions in mice. J Pharm Pharmacol 41: 143-144.
17. Frazer A (1997). Pharmacology of antidepressants. J Clin Psychopharmacol 17(Suppl 1): 2S-18S.
18. Frazer A (2000). Norepinephrine involvement in antidepressant action. J Clin Psychiatr 61(Suppl 10): 25-30.
19. Giorgi FS, Pizzanelli C, Biagioni F, Murri L, Fornai F (2004). The role of norepinephrine in epilepsy: from the bench to the bedside. Neurosci Biobehav Rev 28: 507-524.
20. Gould GG, Benmansour S, Frazer A (2004). Interactions between serotonergic and noradrenergic systems are not responsible for venlafaxine's lack of effect on serotonin (5-HT) and norepinephrine (NE) transporter density. Soc Neurosci Abstr 54: 9.
21. Grant MM, Weiss JM (2001). Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol Psychiatr 49: 117-129.
22. Harden CL (2002). The co-morbidity of depression and epilepsy: epidemiology, etiology, and treatment. Neurology 59(Suppl 4): S48-S55.
23. Huang YH, Maas JW, Hu GH (1980). The time course of noradrenergic pre- and postsynaptic activity during chronic desipramine treatment. Eur J Pharmacol 68: 41-47.
24. Invernizzi RW, Garattini S (2004). Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Neuropsychopharmacol Biol Psychiatr 28: 819-827.
25. Isbister GK, Bowe SJ, Dawson A, Whyte IM (2004). Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 42: 277-285.
26. Jobe PC, Dailey JW, Wernicke JF (1999). A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 13: 317-356.
27. Johnson EK, Jones JE, Seidenberg M, Hermann BP (2004). The relative impact of anxiety, depression, and clinical seizure features on health-related quality of life in epilepsy. Epilepsia 45: 544-550.
28. Kanner AM, Balabanov A (2002). Depression and epilepsy: how closely related are they? Neurology 58(Suppl 5): S27-S39.
29. Kanner AM, Kozak AM, Frey M (2000). The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav 1: 100-105.
30. Kanner AM, Nieto JC (1999). Depressive disorders in epilepsy. Neurology 53(Suppl 2): S26-S32.
31. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD et al (1989). A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 350(Suppl): 60-75.
32. Krahl SE, Clark KB, Smith DC, Browning RA (1998). Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia 39: 709-714.
33. Krahl SE, Senanayake SS, Pekary AE, Sattin A (2004). Vagus nerve stimulation (VNS) is effective in a rat model of antidepressant action. J Psychiatr Res 38: 237-240.
34. Lee KC, Finley PR, Alldredge BK (2003). Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings. Expert Opin Drug Saf 2: 233-247.
35. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR (1985). Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatr 46: 14-19.
36. McIntyre DC, Edson N, Chao G, Knowles V (1982). Differential effect of acute vs chronic desmethylimipramine on the rate of amygdala kindling in rats. Exp Neurol 78: 158-166.
37. Murphy P, Likhodii S, Nylen K, Burnham WM (2004). The antidepressant properties of the ketogenic diet. Biol Psychiatr 56: 981-983.
38. Nestler EJ, McMahon A, Sabban EL, Tallman JF, Duman RS (1990). Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl Acad Sci USA 87: 7522-7526.
39. Parini S, Renoldi G, Battaglia A, Invernizzi RW (2005). Chronic reboxetine desensitizes terminal but not somatodendritic alpha(2)-adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus. Neuropsychopharmacololgy print copy in press (originally published online Jan. 19, 2005 at www.acnp.org/citations/Npp1300661 ).
40. Peterson SL, Trzeciakowski JP, St Mary JS (1985). Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats. Neuropharmacology 24: 941-946.
41. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R (2002). Effects of psychotropic drugs on seizure threshold. Drug Saf 25: 91-110.
42. Pisani F, Spina E, Oteri G (1999). Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia 40(Suppl 10): S48-S56.
43. Raju SS, Noor AR, Gurthu S, Giriyappanavar CR, Acharya SB, Low HC et al (1999). Effect of fluoxetine on maximal electroshock seizures in mice: acute vs chronic administration. Pharmacol Res 39: 451-454.
44. Ressler KJ, Nemeroff CB (1999). Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatr 46: 1219-1233.
45. Richmond R, Zwar N (2003). Review of bupropion for smoking cessation. Drug Alcohol Rev 22: 203-220.
46. Sanacora G, Mason GF, Krystal JH (2000). Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit Rev Neurobiol 14: 23-45.
47. Schachter SC (2004). Vagus nerve stimulation: mood and cognitive effects. Epilepsy Behav 5(Suppl 1): S56-S59.
48. Schank JR, Liles LC, Weinshenker D (2005). Norepinephrine is required for the full anticonvulsant effects of valproic acid in mice. Epilepsy Res (in press).
49. Suzdak PD, Gianutsos G (1985). Parallel changes in the sensitivity of gamma-aminobutyric acid and noradrenergic receptors following chronic administration of antidepressant and GABAergic drugs. A possible role in affective disorders. Neuropharmacology 24: 217-222.
50. Szot P, Weinshenker D, Rho JM, Storey TW, Schwartzkroin PA (2001). Norepinephrine is required for the anticonvulsant effect of the ketogenic diet. Brain Res Dev Brain Res 129: 211-214.
51. Szot P, Weinshenker D, White SS, Robbins CA, Rust NC, Schwartzkroin PA et al (1999). Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. J Neurosci 19: 10985-10992.
52. Thomas SA, Marck BT, Palmiter RD, Matsumoto AM (1998). Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase. J Neurochem 70: 2468-2476.
53. Thomas SA, Matsumoto AM, Palmiter RD (1995). Noradrenaline is essential for mouse fetal development. Nature 374: 643-646.
54. Thomas SA, Palmiter RD (1997). Impaired maternal behavior in mice lacking norepinephrine and epinephrine. Cell 91: 583-592.
55. Weinshenker D, Szot P (2002). The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacol Ther 94: 213-233.
56. Weinshenker D, Szot P, Miller NS, Palmiter RD (2001). Alpha(1) and beta(2) adrenoreceptor agonists inhibit pentylenetetrazole-induced seizures in mice lacking norepinephrine. J Pharmacol Exp Ther 298: 1042-1048.
57. Weinshenker D, White SS, Javors MA, Palmiter RD, Szot P (2002). Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Res 946: 239-246.
58. White CM, Gailey RA, Levin GM, Smith T (1997). Seizure resulting from a venlafaxine overdose. Ann Pharmacother 31: 178-180.
59. Wiegartz P, Seidenberg M, Woodard A, Gidal B, Hermann B (1999). Co-morbid psychiatric disorder in chronic epilepsy: recognition and etiology of depression. Neurology 53(Suppl 2): S3-S8.
60. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP et al (2000). Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatr 47: 818-829.
61. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW et al (2000). Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 3: 465-471.
62. Yan QS, Dailey JW, Steenbergen JL, Jobe PC (1998). Anticonvulsant effect of enhancement of noradrenergic transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): a microinjection study. Brain Res 780: 199-209.
63. Yan QS, Jobe PC, Dailey JW (1993). Noradrenergic mechanisms for the anticonvulsant effects of desipramine and yohimbine in genetically epilepsy-prone rats: studies with microdialysis. Brain Res 610: 24-31.
64. Zienowicz M, Wislowska A, Lehner M, Taracha E, Skorzewska A, Maciejak P et al (2005). The effect of fluoxetine in a model of chemically induced seizures - behavioral and immunocytochemical study. Neurosci Lett 373: 226-231.